Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

I have IGA type of myeloma and undergoing transplant in 5 weeks. I am in a VGPR and have responded very well to D-rvd for 4 months with cycle 5 underway and then cycle 6 and to transplant. My concern is the high risk and praying for long deep remission!

April 24
 · 
Be the first to react
A MyMyelomaTeam Member

Is IGA the more aggressive form? I just read that but have not read that before today!

April 24
A MyMyelomaTeam Member

I am being treated at Princess Margaret Cancer Centre in Toronto, Canada

April 24
MyMyelomaTeam

First, a VGPR after just 4 cycles of D-RVd is a really encouraging sign β€” that kind of strong early response genuinely matters for what comes next. Many MyMyelomaTeam members with high-risk cytogenetics have gone on to reach MRD negativity after transplant, and that is considered one of the best possible outcomes.

Reaching Show Full Answer

First, a VGPR after just 4 cycles of D-RVd is a really encouraging sign β€” that kind of strong early response genuinely matters for what comes next. Many MyMyelomaTeam members with high-risk cytogenetics have gone on to reach MRD negativity after transplant, and that is considered one of the best possible outcomes.

Reaching MRD negative status means no detectable myeloma cells remain after treatment. This is significant because:

- It is one of the strongest indicators of a deeper, longer remission
- It can help guide future maintenance therapy decisions
- Doctors monitor MRD over time to catch any early signs of relapse For high-risk myeloma, the transplant itself combined with maintenance therapy afterward plays a big role in extending remission. Studies show that five-year survival rates after transplant have improved significantly β€” rising from 35% to 63% β€” largely due to better drug combinations used alongside the transplant.

High-risk cytogenetics can influence prognosis, but achieving MRD negativity can help offset some of that risk. Specific chromosome changes that doctors watch in high-risk cases include:

- Deletion of chromosome 13 or 17
- Amplification of part of chromosome 1
- Certain chromosome 14 translocations The most important next step is having an open conversation with your specialist about MRD testing post-transplant and what a maintenance therapy plan might look like for your specific cytogenetics. Being treated at an academic or specialist cancer center also tends to lead to better outcomes, so being proactive about your care team matters.

Wishing you a smooth transplant and that deep, long remission you're hoping for β€” you're clearly doing everything right! πŸ’ͺ

April 24

Related Questions

View All
A MyMyelomaTeam Member asked a question πŸ’­
Lake Charles, LA

A MyMyelomaTeam Member asked a question πŸ’­
Ohio, OH